发明名称 Heterocyclic Compounds and Methods of Their Use
摘要 The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
申请公布号 US2014378430(A1) 申请公布日期 2014.12.25
申请号 US201314370737 申请日期 2013.01.04
申请人 Spinifex Pharmaceuticals Pty Ltd 发明人 McCarthy Thomas David;Naylor Alan
分类号 C07D498/10;C07D209/42;C07D413/04;C07D401/04;C07D403/04;C07D401/12;C07D409/04;C07D205/04;C07D207/14;C07D207/16;C07D471/10 主分类号 C07D498/10
代理机构 代理人
主权项 1. A compound of formula (I):wherein: X is absent and Y is —CHR3CH2—, —CH2CHR3—, —CHR3CHR4CH2—, —CH2CHR3CHR4—, —CH2CH2CHR3—, —CR3═CHCH2—, —CH═CHR3CH2— or —CH2CH═CR3—; or X is —CHR5 and Y is —CHR3—, —CHR3CHR4—, —CHR3CR4═, —CH2CHR3—, —CR3═CH— or —CH═CR3—, wherein when Y is —CHR3CR4═, R2b is absent, or X is —CH2CHR5— or C(═O)CHR5— and Y is —CHR3—; R1 is —C(═O)CHR6R7, —C(═O)NR6R7, —C(═O)CH2CHR6R7, —C(═O)CH═CR6R7, —C(═S)CHR6R7, —C(═S)NR6R7, —C(═S)CH2CHR6R7, —C(═S)CH═CR6R7, —C(═NR8)CHR6R7, —C(═NR8)NR6R7, —C(═NR8)CH2CHR6R7 or —C(═NR8)CH—CR6R7; R2 is —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —OR8, —SR8, —N(R8)2, —C(═O)R8, —C(═O)N(R8)2, —N(R8)C(═O)R8, —N(R8)C(═O)N(R8)2, —N(R8)SO2R8, —SO2N(R8)2, —N(R8)SO2N(R8)2, —W-cycloalkyl, —W-cycloalkenyl, —W-aryl, —W-heterocyclyl, —W-heteroaryl, —W—Z—W-cycloalkyl, —W—Z—W-cycloalkenyl, —W—Z—W-aryl, —W—Z—W-heterocyclyl or —W—Z—W-heteroaryl, ═CH—C(═O)-J-R10, ═CHC(═O)NH-J-R10, —OCH2CHR10C2R10 or —OCH2C(R10)═CHR10; R2b is hydrogen; R3 is a carboxylic acid, —CH2CH2H, —C(═O)C(═O)OH, —CH2OH, —C(═O)NH2, —CN, —CH2C(═O)NH2, —CH2CN, a carboxylic acid bioisostere or —CH2carboxylic acid bioisostere; R4 is hydrogen or R3 and R4 together form a group: where R11 is a carboxylic acid, —CH2CH2H, —C(═O)C(═O)OH, —CH2OH, —C(═O)NH2, —CN, —CH2C(═O)NH2, —CH2CN, a carboxylic acid bioisostere or —CH2carboxylic acid bioisostere; R5 is hydrogen or together with R2 forms a fusedaryl ring substituted with one or two substituents selected from —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, —C1-6alkyleneR10, —C2-6alkenyleneR10, —C2-6alkynyleneR10, —OCH3, —OCHF2, —OR9, —OC1-6alkyleneR10, —OC2-6alkenyleneR10, —OC2-6alkynyleneR10, —SO2NHR9, —NHSO2R9, —NHC(═O)NHR9, —NHC(═O)OR9 or —CH(OH)CH(OH)R9; or a heterocyclyl or heteroaryl ring optionally substituted with one or two optional substituents selected from —CH1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, —C1-6alkyleneR10, —C2-6alkenyleneR10, —C2-6alkynyleneR10, —OCH3, —OCHF2, —OR9, —OC1-6alkyleneR10, —OC2-6alkenyleneR10, —OC2-6alkynyleneR10, —SO2NHR9, —NHSO2R9, —NHC(═O)NHR9, —NHC(═O)OR9 or —CH(OH)CH(OH)R9; R6 and R7 are independently —C1-6alkyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, —CH2aryl, —CH2cycloalkyl, —CH2cycloalkenyl, —CH2heterocyclyl or —CH2heteroaryl; R8 is hydrogen, —C1-8alkyl, —C1-8fluoroalkyl, aryl, —C1-8alkylenearyl, —C2-8alkenylenearyl or —C2-8 alkyylenearyl; R9 is —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, arylcycloalkyl-, arylcycloalkenyl-, arylaryl-, arylheterocyclyl- or arylheteroaryl-; W is a covalent bond, —O—, —S—, —SO—, —SO2—, —N(R8)—, —C(═O)—, —N(R8)C(═O)—, —C(═O)N(R8)—, —CH1-4alkylene-, —C2-4alkenylene-, —CH24 alkynylene-, —C1-3alkyleneQC1-3alkylene-, -QC1-4alkylene-, -QC2-4alkenylene-, -QC2-4alkynylene-, —CH1-4alkyleneQ-, —C2-4alkenyleneQ-, —C2-4 alkynyleneQ-, -QC1-4alkyleneQ-, -QC2-4alkenyleneQ- or —OC2-4alkynyleneQ-; Q is —O—, —S—, —SO—, —SO2—, —N(R8)—, —C(═O)—, —N(R8)C(═O)—, —C(═O)N(R8)—, Z is -cycloalkyl-, -cycloalkenyl-, -aryl-, -heterocyclyl- or -heteroaryl-; J is a covalent bond or —C1-6alkylene-, —C2-6alkenylene- or —C2-6alkynylene, in which one —CH2— group in the alkylene, alkenylene or alkynylene group may be replaced by —O—, —S—, —S(O)—, —S(O)2—, —N(R8)—, —C(═O)—, —C(═O)NH— or —NHC(═O)—; R10 is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl; and wherein each cycloalkyl, cycloalkenyl, aryl, heterocyclyl and heteroaryl may be optionally substituted; or a pharmaceutically acceptable salt thereof.
地址 Preston AU